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KRAS2 mutations in codon 12 have been detected in about 80% of pancreatic cancers. The aim of this study was to evaluate
the value of KRAS2 mutations detection in circulating deoxyribo nucleic acid to differentiate pancreatic cancer from chronic
pancreatitis. Circulating deoxyribo nucleic acid was isolated from serum in 47 patients with histologically proven pancreatic
adenocarcinomas (26 males, median age 65 years) and 31 controls with chronic pancreatitis (26 males, median age 48 years).
Mutations at codon 12 of KRAS2 gene were searched for using polymerase chain reaction and allele speciﬁc ampliﬁcation.
Serum carbohydrate antigen 19.9 levels were also determined. KRAS2 mutations were found in 22 patients (47%) with
pancreatic cancer and in four controls with chronic pancreatitis (13%) (P50.002). None of the latter developed a pancreatic
cancer within the 36 months of median follow-up. The sensitivity, speciﬁcity, positive and negative predictive values of serum
serum KRAS2 mutations for the diagnosis of pancreatic cancer were 47, 87, 85 and 52%, respectively. KRAS2 mutations were
not related to age, gender, smoking habit, tumour stage, or survival. Among the 26 patients with normal or non-contributive
(due to cholestasis) serum carbohydrate antigen 19.9 levels, 14 (54%) had KRAS2 mutations. The combination of KRAS2 and
carbohydrate antigen 19.9 gave a sensitivity, speciﬁcity, positive and negative predictive values for the diagnosis of pancreatic
cancer of 98, 77, 87 and 96%, respectively. Detection of KRAS2 mutations in circulating deoxyribo nucleic acid has a low
sensitivity but a speciﬁcity about 90% for the diagnosis of pancreatic cancer. It seems particularly useful when serum
carbohydrate antigen 19.9 levels are normal or inconclusive. A combined normal serum carbohydrate antigen 19.9 and
absence of circulating KRAS2 mutations makes the diagnosis of pancreatic cancer extremely unlikely.
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Five-year survival in patients with pancreatic adenocarcinomas is
less than 5%, partly due to advanced disease at diagnosis. The
differentiation between pancreatic cancer and chronic pancreatitis
can be particularly difﬁcult leading to inappropriate treatment.
Serum carbohydrate antigen 19.9 (Ca 19.9) levels are elevated in
80% of pancreatic cancer patients, but can also be increased in
20% of patients with chronic pancreatitis (Satake and Takeuchi,
1994; Nouts et al, 1998). Moreover, pancreatic inﬂammation, as
observed in chronic pancreatitis, can be mistaken on imaging as
cancer and inversely. An accurate and non-invasive test to differ-
entiate pancreatic cancer from chronic pancreatitis would be
extremely helpful.
Previous studies have reported KRAS2 gene mutations (almost
always conﬁned to codon 12) in 75 to 95% of exocrine pancreatic
cancer (Caldas and Kern, 1995). KRAS2 mutations provoke activa-
tion of nuclear transcriptor factors, resulting in cellular
proliferation and also in tumour angiogenesis as reported recently
(Banerjee et al, 2000; Ikeda et al, 2001). Detection of KRAS2 muta-
tions were ﬁrst reported in surgically removed pancreatic tumoural
tissue or at autopsy (Almoguera et al, 1988; Tada et al, 1991).
Thereafter mutations were discovered in 63 to 83% of samples of
pure pancreatic juice or main pancreatic duct brushing obtained
during endoscopic retrograde pancreatography (Iguchi et al,
1996; Kondo et al, 1997; Tada et al, 1998; Van Laethem et al,
1998; Okai et al, 1999; Watanabe et al, 1999; Ha et al, 2001; Pugli-
ese et al, 2001; Seki et al, 2001) or at ﬁne-needle tumour aspiration
(Pabst et al, 1999; Puig et al, 2000), and in 20 to 54% of stools
(Caldas et al, 1994; Wenger et al, 1999) from patients with
pancreatic cancer. Circulating deoxyribo nucleic acid (DNA) was
ﬁrst detected in serum or plasma of normal subjects in 1975 (Stein-
man, 1975). Since then, mutations in the KRAS2 gene have been
detected in the plasma of patients with colorectal, lung and haema-
tological cancers (Anker et al, 1997). To date, few studies have
reported KRAS2 mutations in circulating DNA in patients with
pancreatic cancer with a wide spectrum of sensitivity (27 to
81%) (Sorenson et al, 1994; Mulcahy et al, 1998; Yamada et al,
1998; Castells et al, 1999; Porta et al, 1999; Theodor et al, 2000).
The aim of our study was to evaluate the value of KRAS2 mutation
detection in circulating DNA in a large series of patients to differ-
entiate pancreatic adenocarcinoma from chronic pancreatitis.
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Selection and outcome of patients
Between January 1995 and 1999, 47 patients (26 males and 21
females, median age 65 years (range 39–84)) with pancreatic
ductal adenocarcinoma were included in the study. In all of them,
diagnosis was conﬁrmed by pathological examination of pancreatic
tumour obtained by ﬁne needle aspiration during endoscopic ultra-
sonography (n=42) or operative procedure (n=5). Tumour staging
was established by abdominal computed tomography, endoscopic
ultrasonography or operative ﬁndings: stage I (n=5, 11%), stage
II or III (n=19, 40%) and stage IV (n=23, 49%) according to the
TNM classiﬁcation (UICC, 1997). Five patients underwent surgical
resection, 32 patients received systemic chemotherapy and/or
radiotherapy and 10 symptomatic treatment. Median follow-up
was 6 months (range 1–24). At the end of the study, all but four
patients with pancreatic cancer were dead.
Control group
A control group was recruited during the same time in the same
centre and included 31 patients with chronic pancreatitis (26
men and ﬁve women, median age 48 years (range 20–64)). Diag-
nosis of chronic pancreatitis relied upon the presence of pancreatic
calciﬁcations and/or irregularity of pancreatic ducts, according to
Cambridge Classiﬁcation (Axon et al, 1984) on computed tomo-
graphy scan and endoscopic retrograde pancreatography,
respectively. Etiology of chronic pancreatitis was alcoholic in 30
patients and idiopathic in one patient. No case of pancreatic cancer
occurred during the 36-month follow-up in these 31 patients.
DNA extraction and quantiﬁcation
Peripheral venous blood samples were collected after informed
consent in patients and controls. Blood samples were centrifuged,
serum was removed and stored at 7208C until use. DNA was
extracted from serum by using the QIAmp Blood Kit (Qiagen,
Courtaboeuf, France) according to the blood and body ﬂuid proto-
col recommended by the manufacturer. Two millilitres of serum
were used, and a DNA elution volume of 50 ml was obtained by
extraction. The DNA elution was then concentrated to a ﬁnal
volume of 15 ml.
Quantiﬁcation of serum DNA was performed for all samples
using a volume of 3 ml of DNA elution obtained after Qiagen
extraction by ﬂuorescence emission after intercalation of Hœschst
dye. The ﬂuorescence was read by DyNA Quanto ˆ 200 ﬂuorimeter,
using the cuve and capillary DyDNA Capillary Cuvette Adaptor Kit
(Pharmacia Biotech, Orsay, France). The threshold of DNA detec-
tion established by the manufacturer is 2 ng ml
71, which
corresponds to 100 ng ml
71 serum in our extraction protocol
(Coulet et al, 2000).
Detection of KRAS2 gene mutations
Only G12D mutations in codon 12 of the KRAS2 gene were
searched for using allele-speciﬁc ampliﬁcation, with the following
primers: 5'-CTTGTGGTAGTTGGAGCTAA-3',5 '-AATGGTCCT-
GCACCAGTAATATG-3'. Ampliﬁcations were performed with
0.3 mM of each primers, 200 mM of each deoxynucleotide tripho-
sphate (dNTP), 1.5 mM of MgCl2, 0.025 units per mlo f
AmpliTaq Gold polymerase Cetus (Perkin Elmer), 2.5 mlo r5ml
of 106 buffer, 5 ml of the concentrated DNA elution was used
as template in a 50 ml volume reaction. Polymerase chain reaction
(PCR) with serum DNA was performed 10 min at 948C, followed
by 60 cycles of 948C for 30 s, 618C for 30 s, 728C for 1 min and a
ﬁnal extension of 10 min at 728C. Controls without DNA and
positive controls were performed for each set of PCR reactions.
PCR products were separated by electrophoresis in a 6% acryla-
mide gel and stained with ethidium bromide.
Serum Ca 19.9 dosage
The serum value of Ca 19.9 was measured with a commercial solid-
phase double-antibody sandwich immunoassay (Roche Labora-
tories, Basel, Switzerland). The upper limit of normal value was
37 UI ml
71. All patients and controls also underwent biochemical
liver tests. Cholestasis was deﬁned by alkaline phosphatase levels
above twice the normal value.
Statistical analysis
For each marker (serum KRAS2 mutations and Ca 19.9), sensitiv-
ity, speciﬁcity, positive and negative predictive values were
calculated. Thereafter, the combination of both markers (i.e., one
and/or the other positive) was studied. The chi-squared test was
used to compare the occurrence of KRAS2 mutations. Differences
were considered signiﬁcant when P50.05.
RESULTS
Circulating DNA quantiﬁcation
Adequate DNA was extracted from the serum in sufﬁcient quanti-
ties for analysis in all patients and controls. All patients but one
had a serum DNA concentration higher than the threshold of
detection of 100 ng ml
71. The mean concentrations of DNA
extracted from serum of patients with pancreatic cancer and
chronic pancreatitis were 730+90 ng ml
71 and 560+93 ng ml
71,
respectively (P=0.19).
KRAS2 mutations in circulating DNA
KRAS2 mutations were identiﬁed in the serum of 22 patients
(47%) with pancreatic adenocarcinoma and in four patients
(13%) with chronic pancreatitis (P50.002). The sensitivity, speci-
ﬁcity, positive and negative predictive values of serum KRAS2
mutations for the diagnosis of pancreatic cancer were 47, 87, 85
and 52%, respectively. There were no statistically signiﬁcant differ-
ences in age, gender, smoking, tumour stage and survival,
according to presence or absence of plasma KRAS2 mutations.
Among patients with chronic pancreatitis, no cancer occurred
after a mean follow-up of 36 months (range 13–64), even in those
with positive KRAS2 mutations (with follow-up of 40 months,
range 20–61), assessed by clinical observation and abdominal
computed tomography scan.
Serum Ca 19.9 levels
The sensitivity, speciﬁcity, positive and negative predictive values of
abnormal Ca 19.9 levels for the diagnosis of pancreatic cancer were
91, 87, 91 and 87%, respectively (Table 1). Serum Ca 19.9 levels
were normal or non interpretable due to cholestasis in 26 patients.
Among them, 14 (54%) patients had serum KRAS2 mutations.
Combination of both tests increased sensitivity to 98% with a
negative predictive value of 96% for the diagnosis of pancreatic
cancer (Table 1).
DISCUSSION
In the present study, only the most frequent KRAS2 gene muta-
tion G12D (aspartic acid) observed in pancreatic cancer (Iguchi
et al, 1996; Tada et al, 1998; Castells et al, 1999; Watanabe et
al, 1999) was analysed in the serum of patients and controls, in
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practice.
Our study underlines the high feasibility of KRAS2 mutations
analysis, as circulating DNA was obtained in sufﬁcient quantities
in all patients. Mean serum DNA concentration were 730 ng ml
71,
which is comparable to that observed in the series of Mulcahy et al
(1998).
In the present study, detection of KRAS2 mutations in circulat-
ing DNA had a low sensitivity but a high speciﬁcity for the
diagnosis of pancreatic cancer. The sensitivity (47%) was in agree-
ment with previous studies (27 to 81%) (Mulcahy et al, 1998;
Yamada et al, 1998; Castells et al, 1999; Porta et al, 1999; Theodor
et al, 2000; Zambon et al, 2000), although the search for ﬁve other
possible KRAS2 mutations in codon 12 was not performed. Higher
KRAS2 mutation prevalences have been reported in pancreatic or
duodenal juice (63 to 87%), due probably to higher DNA tumour
content in pancreatic juice as compared to plasma (Wilentz et al,
1998; Van Laethem et al, 1998; Watanabe et al, 1999). Use of
samples of pancreatic juice however requires invasive procedures
(ﬁne-needle aspiration during endoscopic ultrasonography or
endoscopic retrograde pancreatography). Three studies have
reported a higher speciﬁcity of serum KRAS2 mutations compared
to the current study (100 vs 87%), but their control groups
included few patients and essentially healthy subjects (Mulcahy et
al, 1998; Porta et al, 1999; Theodor et al, 2000). Since KRAS2
mutations have been reported in pancreatic tissue or juice from
6–42% of patients with chronic pancreatitis (Furuya et al, 1997;
Mulligan et al, 1999; Lu ¨ttges et al, 2000; Ha et al, 2001), and know-
ing that a part of this mutated DNA can be released into
circulation (Yamada et al, 1998), the control group should include
patients with chronic pancreatitis. In the series published by
Castells et al (1999) with the largest control group (including
patients with chronic pancreatitis), speciﬁcity was comparable
(94%) to the present study, and increased in the presence of a
pancreatic mass. The accuracy of serum KRAS2 mutation detection
in the differential diagnosis between pancreatic cancer and chronic
pancreatitis may be improved by performing quantitative PCR
measurement of mutated DNA, in order to discriminate patients
with unspeciﬁc low levels of mutated DNA (as supposed in chronic
pancreatitis) from patients with high levels (pancreatic cancer), as
suggested in pancreatic juice analysis by Tada et al (1998).
Serum Ca 19.9 is widely used for pancreatic cancer diagnosis
with a sensitivity of 80% (Satake and Takeuchi, 1994). This marker
is not informative in 5% of population who cannot express serum
Ca 19.9 due to Lewis a negative status (Narimatsu et al, 1996).
However, serum Ca 19.9 lacks speciﬁcity (70 to 80%): it can be
increased in cholestasis, diabetes mellitus or chronic pancreatitis
(Nouts et al, 1998). In the present study, serum Ca 19.9 had very
good speciﬁcity (87%), similar to that of serum KRAS2 mutations.
Combination of both tests could be useful to assess cancer diagno-
sis in patients with normal or non contributive Ca 19.9 due to
cholestasis or negative Lewis a antigen status, and to exclude cancer
diagnosis when both tests are negative (predictive negative value of
96%).
In the present study, the presence of KRAS2 mutations in
serum was not correlated to age, gender and smoking habit. It
was neither correlated to tumour stage since mutations were
detected in plasma of patients with non metastatic tumours,
which supports the hypothesis that KRAS2 mutations are early
events in pancreatic carcinogenesis (Jimenez et al, 1999). Two
studies in the literature are in agreement with this result (Yamada
et al, 1998; Theodor et al, 2000), but another one found a statis-
tically signiﬁcant relation between circulating DNA KRAS2
mutations and poor prognosis (Castells et al, 1999). Yamada et
al (1998) have reported disappearance of detectable mutation in
plasma after tumoural resection or radio-chemotherapy in six of
nine patients, suggesting KRAS2 mutations may be used as a
tumour relapse marker.
Screening for malignancy in patients with chronic pancreatitis is
a difﬁcult challenge. Patients with chronic pancreatitis have an
increased risk of pancreatic cancer, estimated at 1.8% at 10 years
and 4% at 20 years (Lowenfels et al, 1993). Three studies have eval-
uated occurrence of pancreatic cancer in patients with chronic
pancreatitis with respect to KRAS2 mutations in pancreatic juice:
only one found an increase in pancreatic cancer in patients with
KRAS2 mutations with methodological limitations (few cases, early
diagnosis of cancer after inclusion) (Furuya et al, 1997; Lohr et al,
2001; Queneau et al, 2001). To our knowledge, no study focused
on the incidence of pancreatic cancer in patients with chronic
pancreatitis according to serum KRAS2 mutations. In the present
study, follow-up was too short to demonstrate an increased risk
of cancer in patients with chronic pancreatitis and serum KRAS2
mutations.
In conclusion, although detection of plasma KRAS2 mutations
in circulating DNA is not a deﬁnitive argument for malignancy,
it could contribute to cancer diagnosis. This test seems particularly
interesting in patients with normal or inconclusive Ca 19.9 levels
due to cholestasis or Lewis a negative status. In patients with
normal serum Ca 19.9 levels and no KRAS2 mutation, the diagno-
sis of pancreatic cancer can be excluded with almost certainty.
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